Join
Live feed
·
PRReleasevia Quantisnow
Aligos Therapeutics Inc. logo

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

ByQuantisnow·Wall Street's wire, on your screen.
ALGS· Aligos Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALGS (Aligos Therapeutics Inc.) and more on Quantisnow.